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Abstract
Background: Gonadotrophins are routinely administered in assisted reproductive technology
(ART) treatment protocols. Recombinant human follicle-stimulating hormone (r-hFSH; follitropin
alfa) and recombinant human luteinizing hormone (r-hLH; lutropin alfa) can be administered
individually or in a fixed combination. The ability to vary the FSH to LH dose ratio in a single
injection without compromising the bioactivity of either gonadotrophin or generating losses of
active principle is important for physicians and patients alike.
Methods: This study investigated whether follitropin alfa (GONAL-f (R)), as lyophilized powder
for reconstitution or solution from the GONAL-f (R) (filled-by-mass [FbM]) Prefilled Pen, could be
used to reconstitute Pergoveris TM (follitropin alfa/lutropin alfa 150 IU/75 IU) lyophilized powder.
In Ratio Groups 1 and 2, the r-hFSH:r-hLH ratio was 3:1; in Ratio Groups 3 and 4, the ratios of r-
hFSH:r-hLH were 5:1 and 8:1, respectively. The protein content and bioactivity of each mixed
solution were evaluated. The r-hFSH and r-hLH content was determined using reverse-phase high
performance liquid chromatography. The biological activity of r-hFSH and r-hLH was assessed using
the Steelman-Pohley and Van Hell in vivo bioassays in rats, respectively.
Results: Follitropin alfa/lutropin alfa 150 IU/75 IU lyophilized powder could be successfully mixed
with follitropin alfa 75 IU FbM solution that was either reconstituted from lyophilized powder or
injected directly from the prefilled pen to create solutions with ratios of r-hFSH and r-hLH from
3:1 to 8:1. The measured content of r-hFSH and r-hLH corresponded favourably with the target
protein content in Ratio Groups 1–4. The in vivo target and measured bioactivity of r-hFSH and r-
hLH were also closely matched in all Ratio Groups.
Conclusion:  Follitropin alfa lyophilized powder or solution can be accurately mixed with
follitropin alfa/lutropin alfa 150 IU/75 IU lyophilized powder to enable physicians to administer
ratios of r-hFSH and r-hLH in the IU range from 3:1 to 8:1. Mixing of recombinant formulations
offers flexibility for patients receiving follitropin alfa and lutropin alfa for ART protocols in clinical
practice.
Background
Gonadotrophins are routinely administered in many
assisted reproductive technology (ART) treatment proto-
cols. Follicle-stimulating hormone (FSH) induces the
recruitment and development of ovarian follicles and
luteinizing hormone (LH) increases oestradiol secretion
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by the follicles and is responsible for final oocyte matura-
tion and subsequent ovulation [1]. Recombinant human
FSH (r-hFSH; follitropin alfa) and LH (r-hLH; lutropin
alfa) can be administered independently or in combina-
tion, in accordance with individual patient needs.
Various injection devices have been developed to simplify
administration of gonadotrophins and allow patients to
self-administer treatment [2]. Follitropin alfa (filled-by-
mass [FbM]) is provided in ready-to-use, prefilled pens
that are designed specifically for self-administration by
patients [2,3]. The GONAL-f® (FbM) Prefilled Pen is avail-
able in three multi-dose formulations (300, 450 and 900
IU) and does not require reconstitution or cartridge
assembly into the injection device, thereby reducing the
number of steps before injection and helping to ensure an
accurate and correct dose [2,3]. Follitropin alfa (FbM) is
also available in single (75 IU) and multidose (450 and
1050 IU) vials of lyophilized powder for reconstitution.
The variety of commercially available preparations
accommodates individualized dosing for diverse proto-
cols for ovulation induction or controlled ovarian stimu-
lation.
r-hFSH and r-hLH have been recently combined in a sin-
gle product (Pergoveris™ [follitropin alfa/lutropin alfa
150 IU/75 IU]), thereby allowing administration of both
gonadotrophins in a convenient single injection [4]. Foll-
itropin alfa/lutropin alfa 150 IU/75 IU is indicated for the
stimulation of follicular development in women who are
infertile because of severe endogenous FSH and LH defi-
ciencies [4].
An increasing number of physicians are requesting infor-
mation on the feasibility of mixing the currently available
recombinant gonadotrophin products. Therefore, we eval-
uated the protein content and in vivo bioactivity of folli-
tropin alfa and lutropin alfa in rats after mixing follitropin
alfa/lutropin alfa 150 IU/75 IU lyophilized powder with
follitropin alfa as 75 IU FbM lyophilized powder or solu-
tion from the GONAL-f® (FbM) Prefilled Pen.
Methods
Materials
Commercially-available formulations of recombinant
gonadotrophins were tested: follitropin alfa/lutropin alfa
150 IU/75 IU [Pergoveris™] lyophilized powder; follitro-
pin alfa (GONAL-f®) as 75 IU FbM lyophilized powder (in
3 mL glass vials) supplied by Laboratoires Serono S.A.
(Aubonne, Switzerland) and 900 IU GONAL-f® (FbM)
Prefilled Pen supplied by Merck Serono S.p.A. (Bari,
Italy).
Water for injection (WFI) was supplied by Galenica Sen-
ese (Siena, Italy). Reagents used for the high performance
liquid chromatography (HPLC) analysis were supplied by
Merck Serono S.A. – Geneva (Switzerland).
Gonadotrophin mixing procedures
Follitropin alfa/lutropin alfa 150 IU/75 IU and follitropin
alfa were mixed according to the procedures described
below to provide different ratios of r-hFSH and r-hLH
ranging from 3:1 to 8:1 (Table 1). In Ratio Groups 1 and
2, the r-hFSH:r-hLH ratio was 3:1, whereas the ratios of r-
hFSH:r-hLH in Ratio Groups 3 and 4 were 5:1 and 8:1,
respectively. A single stock solution was prepared for each
Ratio Group (1–4) on study day 1 and stored at 2–8°C for
the duration of the administration period. In all cases, fol-
litropin alfa solution was added to follitropin alfa/lutro-
pin alfa 150 IU/75 IU lyophilized powder using plastic
syringes, and the final reconstituted volume was approxi-
mately 1 mL.
Ratio Group 1: 75 IU in 1 mL follitropin alfa (75 IU) plus follitropin 
alfa/lutropin alfa 150 IU/75 IU (r-hFSH:r-hLH ratio 3:1)
Step 1: A vial containing follitropin alfa 75 IU lyophilized
powder was reconstituted with 1 mL of WFI using a 1 mL
plastic syringe with 22 GA × 1" needle. Step 2: The vial was
gently mixed until the cake was completely dissolved. Step
Table 1: r-hFSH and r-hLH mixing scheme*
Follitropin alfa/lutropin alfa 150 IU/75 IU Follitropin alfa 75 IU Follitropin alfa 900 IU r-hFSH:r-hLH ratio
Ratio Group 1 FSH 150 IU 75 IU in 1 mL -- 3:1
LH 75 IU -- --
Ratio Group 2 FSH 150 IU -- 75 IU in 0.125 mL 3:1
LH 75 IU -- --
Ratio Group 3 FSH 150 IU 225 IU in 1 mL -- 5:1
LH 75 IU -- --
Ratio Group 4 FSH 150 IU -- 450 IU in 0.75 mL 8:1
LH 75 IU -- --
r-hFSH, recombinant human follicle-stimulating hormone; r-hLH, recombinant human luteinizing hormone.
*Follitropin alfa was reconstituted with water for injection and then added to follitropin alfa/lutropin alfa lyophilized powder. The final reconstituted 
volume was always approximately 1 mL.Reproductive Biology and Endocrinology 2009, 7:48 http://www.rbej.com/content/7/1/48
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3: The solution was withdrawn from the vial of follitropin
alfa using a 1 mL graduated plastic syringe with 22 GA ×
1" removable needle. Step 4: The solution was then trans-
ferred into the vial containing follitropin alfa/lutropin
alfa 150 IU/75 IU lyophilized powder. Step 5: The vial was
gently mixed until the cake was completely dissolved. The
needle used for withdrawing was replaced with a 27 GA ×
1/2" needle and the solution was injected into a con-
tainer.
Ratio Group 2: 75 IU in 0.125 mL follitropin alfa (900 IU GONAL-
f® [FbM] Prefilled Pen) plus follitropin alfa/lutropin alfa 150 IU/75 
IU (r-hFSH:r-hLH ratio 3:1)
Step 1: 0.125 mL (75 IU) of follitropin alfa was injected
from a 900 IU prefilled pen into a vial containing follitro-
pin alfa/lutropin alfa 150 IU/75 IU lyophilized powder.
Step 2: 0.875 mL of WFI was added to the vial containing
follitropin alfa/lutropin alfa 150 IU/75 IU lyophilized
powder and follitropin alfa using a 1 mL graduated plastic
syringe with 22 GA × 1" removable needle. The method-
ology was completed according to Step 5, Ratio Group 1
(above).
Ratio Group 3: 225 IU in 1 mL follitropin alfa (75 IU) plus follitropin 
alfa/lutropin alfa 150 IU/75 IU (r-FSH:r-LH ratio 5:1)
Step 1: A vial containing follitropin alfa 75 IU lyophilized
powder was reconstituted with 1 mL of WFI using a 1 mL
plastic syringe with 22 GA × 1" needle. The vial was gently
mixed until the cake was completely dissolved. Step 2: The
solution was withdrawn from the first vial of follitropin
alfa 75 IU and transferred into a second vial also contain-
ing follitropin alfa 75 IU using the 1 mL graduated plastic
syringe with 22 GA × 1" removable needle. The second
vial was gently mixed until the cake was completely dis-
solved. Step 3: The solution was withdrawn from the sec-
ond vial of follitropin alfa 75 IU and transferred into a
third vial containing follitropin alfa 75 IU lyophilized
powder using the 1 mL graduated plastic syringe with 22
GA × 1" removable needle. The third vial was gently
mixed until the cake was completely dissolved. Step 4: As
much solution as possible was withdrawn from the third
vial of follitropin alfa 75 IU using a 1 mL graduated plastic
syringe with 22 GA × 1" removable needle and transferred
into a vial of follitropin alfa/lutropin alfa 150 IU/75 IU
lyophilized powder. The methodology was completed
according to Step 5, Ratio Group 1 (above).
Ratio Group 4: 450 IU in 0.75 mL follitropin alfa (900 IU GONAL-
f® [FbM] Prefilled Pen) plus follitropin alfa/lutropin alfa 150 IU/75 
IU (r-FSH:r-LH ratio 8:1)
Step 1: 0.75 mL (450 IU) of follitropin alfa was injected
from a 900 IU prefilled pen into a vial containing follitro-
pin alfa/lutropin alfa 150 IU/75 IU lyophilized powder.
Step 2: Using a 1 mL graduated plastic syringe with 22 GA
× 1" removable needle, 0.25 mL of WFI was added to the
vial containing follitropin alfa/lutropin alfa 150 IU/75 IU
lyophilized powder and follitropin alfa. The methodology
was completed according to Step 5, Ratio Group 1
(above).
Analytical methods
The protein content and in vivo bioactivity of each r-hFSH
and r-hLH solution were measured after mixing.
Determination of the protein content of r-hFSH and r-hLH mixed 
solutions
The target protein content of each mixed solution was cal-
culated using the following conversion factors: 150 IU r-
hFSH corresponds with 10.8 mcg; 75 IU r-hLH corre-
sponds with 3 mcg. Chromatography of the prepared
solutions was performed on a reverse-phase-HPLC (RP-
HPLC, Waters) column (source: 5RPC 4.6 × 150 mm),
using a gradient of 0.1% trifluoroacetic acid/acetonitrile
in 0.1% trifluoroacetic acid/water. The two subunits of r-
hFSH and r-hLH were separated and the peaks relative to
the beta subunits of each protein were quantified as a pro-
portion of the beta subunits of their respective standards.
In vivo bioassay for r-hFSH biological activity
The in vivo bioactivity of FSH was assessed according to
current US and European Pharmacopoeias by the tradi-
tional Steelman-Pohley human chorionic gonadotrophin
(hCG) augmentation assay (1953), which measures ovar-
ian hypertrophy following administration of exogenous
FSH (in combination with hCG) to immature female rats
[5].
Animal groups of five, 21-day-old female Sprague-Dawley
rats (Harlan-Nossan, Italy) weighing 42–52 g were used
for each bioassay. The rats were injected with both the fol-
litropin alfa/lutropin alfa mixed solution and hCG (Ovit-
relle®) for 3 days; they received one dose on day 1 and two
doses on days 2 and 3. On day 4, the rats were sacrificed
and their ovaries were removed, excised of fat and connec-
tive tissue and weighed. Each sample was tested in tripli-
cate (using three independent replicates). The internal
Merck Serono S.A. – Geneva Standard was previously cal-
ibrated against the National Institute for Biological Stand-
ard and Controls (NIBSC) International Standard
(recombinant follicle stimulating hormone, IS 92/642).
In vivo bioassay for r-hLH biological activity
The in vivo bioactivity of LH was assessed according to US
and European Pharmacopoeias following the Van Hell
seminal vesicle weight gain bioassay [6].
Animal groups of five, 21-day-old male SPF Sprague-Daw-
ley rats (Harlan-Nossan) weighing 42–52 g were used.
Rats were injected with one subcutaneous daily dose (0.5
mL) of the follitropin alfa/lutropin alfa 150 IU/75 IU andReproductive Biology and Endocrinology 2009, 7:48 http://www.rbej.com/content/7/1/48
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follitropin alfa mixed solution for 4 days. On day 5, 96
hours after the first administration, the animals were sac-
rificed and the seminal vesicles were removed and
weighed. Each sample was tested in triplicate. The internal
Merck Serono S.A. – Geneva Standard was previously cal-
ibrated against the NIBSC International Standard (recom-
binant luteinizing hormone, IS 71/264).
Animal care
Animal studies were authorized by the Italian Health
Authority (Ministero della Salute) in accordance with the
government decree D.L. 116/92 and the 86/609/CEE
directive. All animals were kept in 12 hours of light and 12
hours of dark conditions, and each experimental animal
group was housed in separate cages. Rats were given access
to food and water ad libitum throughout the study.
Results
Follitropin alfa/lutropin alfa 150 IU/75 IU lyophilized
powder could be mixed successfully with follitropin alfa
75 IU FbM solution that was either reconstituted from
lyophilized powder or injected directly from the GONAL-
f® (FbM) Prefilled Pen. Using these commercially available
formulations, it was possible to create solutions with
ratios of r-hFSH and r-hLH in the range from 3:1 to 8:1.
Furthermore, no practical issues such as needle bending
were experienced during the addition of follitropin alfa
solution from the prefilled pen to follitropin alfa/lutropin
alfa 150 IU/75 IU lyophilized powder.
The r-hFSH and r-hLH content and in vivo bioactivity of
mixed solutions of follitropin alfa/lutropin alfa 150 IU/75
IU lyophilized powder and follitropin alfa are presented
in Table 2. The measured protein content of r-hFSH and r-
hLH corresponded closely with the target amount; the
coefficient of variation ranged from 0.3 to 1.2% for r-
hFSH and from 1.1 to 2.9% for r-hLH. The measured bio-
activity of r-hFSH and r-hLH also corresponded closely
with the target amount. Thus, both the measured protein
content and in vivo bioactivity of r-hFSH and r-hLH in
Ratio Groups 1–4 corresponded favourably with the target
amounts.
Discussion
Infertility treatment protocols are individualized accord-
ing to a variety of factors, including the patient's age and
diagnosis, ovarian reserve and any co-administered medi-
cations. Owing to the complexity of treatment protocols,
patients prefer to use the fewest possible number of steps
to prepare each injection [7]. Accordingly, the ability to
vary the FSH to LH dose ratio in a single injection is
important for both physicians and patients.
The pharmacokinetics of follitropin alfa and lutropin alfa
administered individually or mixed together was first
reported by le Cotonnec et al. [8-13]. The authors found
no evidence of pharmacokinetic or pharmacodynamic
interactions between follitropin alfa and lutropin alfa.
More recently, it has been demonstrated that r-hLH and r-
hFSH can be mixed together in the same syringe without
compromising the bioactivity of the gonadotrophins [14],
and administered successfully to patients [15]. Purified
urinary gonadotrophin products can also be reconstituted
and mixed together in a single syringe without affecting
the FSH or LH bioactivity [16].
The present study was conducted to assess the feasibility
of reconstituting follitropin alfa/lutropin alfa 150 IU/75
IU lyophilized powder using currently marketed formula-
tions of follitropin alfa FbM solution. The results demon-
strate that follitropin alfa FbM either as 75 IU lyophilized
powder or multi-dose solution from a prefilled pen may
be mixed with follitropin alfa/lutropin alfa 150 IU/75 IU
lyophilized powder to produce solutions with ratios of
follitropin alfa to lutropin alfa from 3:1 to 8:1.












Ratio Group 1 (n = 15) r-hFSH 16.2 16.5 1.2 225 216
r-hLH 3.0 3.4 1.7 75 77
Ratio Group 2 (n = 15) r-hFSH 16.2 17.4 0.9 225 221
r-hLH 3.0 3.5 2.9 75 76
Ratio Group 3 (n = 15) r-hFSH 27.0 26.9 1.1 375 339
r-hLH 3.0 3.5 1.1 75 73
Ratio Group 4 (n = 15) r-hFSH 43.2 45.4 0.3 600 568
r-hLH 3.0 3.5 2.9 75 77
CV, coefficient of variation; r-hFSH, recombinant human follicle-stimulating hormone; r-hLH, recombinant human luteinizing hormone.
The target protein content was calculated using the following conversion factors: 150 IU r-hFSH corresponds with 10.8 mcg; 75 IU r-hLH 
corresponds with 3 mcg.
*All bioactivity measurements fell within the 80 – 125% of target, as specified by the United States Pharmacopeia for product labelling [20].Reproductive Biology and Endocrinology 2009, 7:48 http://www.rbej.com/content/7/1/48
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Regulatory bodies designate that the Steelman-Pohley and
Van Hell seminal vesicle weight gain in vivo bioassays are
used to determine the gonadotrophin content of commer-
cial FSH and LH products [5,6]. However, the inherent
lack of precision of these bioassays is well recognized [17-
19]. To allow for this variability, it is specified in the
United States Pharmacopeia, that gonadotrophin formu-
lations should contain between 80% and 125% of the
hormones listed on the product label [20].
In this study, the bioactivity of FSH and LH as assessed by
the established in vivo bioassays fell well within these
bounds. Thus, the bioactivity of FSH and LH was unaf-
fected after mixing using plastic syringes and following
the methodology described. The follitropin alfa and lutro-
pin alfa protein content of the mixed solutions was also
assessed by an accurate RP-HPLC assay, which confirmed
the expected recoveries.
The flexibility in dosing ratios of follitropin alfa and lutro-
pin alfa afforded by mixing facilitates further individuali-
zation of therapy according to each patient's individual
gonadotrophin requirements.
Conclusion
Follitropin alfa can be mixed accurately with follitropin
alfa/lutropin alfa 150 IU/75 IU lyophilized powder to
enable physicians to administer different ratios of r-hFSH
and r-hLH in the IU range from 3:1 to 8:1. Mixing of
recombinant formulations is expected to offer flexibility
for patients receiving follitropin alfa and lutropin alfa for
ART protocols in clinical practice.
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